Sugi Predict

Sugi Predict / Targets / DBH

DBH

Dopamine beta-hydroxylase · P09172 · DBH on Sugi Atlas →

5,771 patent compounds predicted against DBH, 3,772 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3179236 SCHEMBL3179236 0.55 11/20
SCHEMBL3165018 SCHEMBL3165018 0.53 6/20
SCHEMBL3373762 SCHEMBL3373762 0.47 4/20
SCHEMBL524434 SCHEMBL524434 1.00 3/20
SCHEMBL524707 SCHEMBL524707 1.00 3/20
Tropolone Tropolone (SCHEMBL531387) 0.94 3/20
Tropolone Tropolone (SCHEMBL122962) 0.76 3/20
Tropolone Tropolone (SCHEMBL525181) 0.73 3/20
SCHEMBL344192 SCHEMBL344192 0.59 3/20
SCHEMBL122963 SCHEMBL122963 0.58 3/20
SCHEMBL1319163 SCHEMBL1319163 0.58 3/20
Pyrogallol Pyrogallol (SCHEMBL483095) 0.57 3/20
Pyrogallol Pyrogallol (SCHEMBL2063415) 0.57 3/20
Pyrogallol Pyrogallol (SCHEMBL1668793) 0.55 3/20
SCHEMBL1520933 SCHEMBL1520933 0.54 3/20
Alpha-Thujaplicin Alpha-Thujaplicin (SCHEMBL355646) 0.50 3/20
SCHEMBL916360 SCHEMBL916360 0.44 3/20
Pyrogallol Pyrogallol (SCHEMBL2879498) 0.43 3/20
SCHEMBL242968 SCHEMBL242968 0.37 3/20
SCHEMBL3684644 SCHEMBL3684644 0.37 3/20

Clinical trials — most relevant to DBH by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A PET Exploration of the Mechanism of Action of Dopamine Beta-hydroxylase Inhibition in Cocaine Addicts PHASE4WITHDRAWN
Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension PHASE4COMPLETED
Effects of Genotype on Resting State Connectivity During Methamphetamine Administration PHASE4COMPLETED
Galantamine for Cognitive Deficits in Schizophrenia PHASE2/PHASE3COMPLETED
New Treatment for Alcohol and Nicotine Dependence PHASE2/PHASE3COMPLETED
Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) PHASE3COMPLETED
A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease PHASE3COMPLETED
Disulfiram for Cocaine Abuse in Buprenorphine Treatment PHASE2COMPLETED
Phase I/II Study of NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease. PHASE1/PHASE2RECRUITING
Pharmacogenetics of Disulfiram for Cocaine PHASE2COMPLETED
Multiple N-of-1 Trials of (Intermittent) Hypoxia Therapy in Parkinson's Disease PHASE1/PHASE2COMPLETED
A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease PHASE2COMPLETED
Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease (Protocol 53136) PHASE2ACTIVE_NOT_RECRUITING
Early Study of N-Acetylcysteine to Treat Deliberate Self-Harm in Adolescents PHASE1COMPLETED
The Association Between Executive Functions and Candidate Genes of Dopaminergic and Noradrenergic Systems in Attention Deficit Hyperactivity Disorder (ADHD) nanCOMPLETED
Neural Response to Catecholamine Depletion in Subjects Suffering From Bulimia Nervosa in Their Past and Healthy Controls nanSUSPENDED
Direct and Cross Effects of Adaptation to Systemic Hyperthermia: Impact on Quality of Life, Neurohormonal and Psychophysiological Human Status nanCOMPLETED
Behavioural Addiction and Genetics in Parkinson's Disease nanCOMPLETED
Iron Status in Children With ADHD nanNOT_YET_RECRUITING
Brain Tissue Integrity and Autonomic Function Alterations in Childhood OSA and ADHD, and After Adenotonsillectomy. nanUNKNOWN
Human Adaptation to High Altitude nanUNKNOWN
An Open Label Phase I/II Study of the Safety and Dopamine Transporter Binding Properties of C-11 Altropane in Normal Human Subjects and in Subjects With ADHD nanCOMPLETED
Endophenotype, Molecular Genetic Study on Attention-Deficit/Hyperactivity Disorder nanCOMPLETED
Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography nanCOMPLETED
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia nanUNKNOWN
Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome nanCOMPLETED
Prevalence of High Plasmatic 3OMethyldopa Level in a Specific Population of Patients With a Symptomatology Compatible With AADC Deficiency nanUNKNOWN
Effect of Vitamin D Administration Along With SSRIs in Patients With Major Depressive Disorder nanUNKNOWN
Efficacy Study of Light Therapy as an Adjunctive Treatment for Parkinson's Disease nanCOMPLETED
PET Scanning of Adults With Attention Deficit Hyperactivity Disorder (ADHD) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a DBH binder may also engage these)

ProteinNameSimilarity
P15101 — 1.000 P15101 →
Q6UVY6 — 0.999 Q6UVY6 →
Q9XTA0 — 0.997 Q9XTA0 →
Q64237 — 0.996 Q64237 →
Q05754 — 0.994 Q05754 →
Q68CI2 — 0.993 Q68CI2 →
Q9CXI3 — 0.992 Q9CXI3 →
Q08CS6 — 0.988 Q08CS6 →
Q5TZ24 — 0.986 Q5TZ24 →
INSRR Insulin receptor-related protein 0.985 landscape →
Q3U435 — 0.985 Q3U435 →
Q96SM3 — 0.985 Q96SM3 →
Q7TT41 — 0.984 Q7TT41 →
P14617 — 0.984 P14617 →
Q86B61 — 0.984 Q86B61 →
Q8BG22 — 0.983 Q8BG22 →
TMPRSS6 Transmembrane protease serine 6 0.983 landscape →
Q6IE64 — 0.983 Q6IE64 →
Q64716 — 0.983 Q64716 →
Q8N3T1 — 0.983 Q8N3T1 →
Q5M936 — 0.983 Q5M936 →
Q499S5 — 0.983 Q499S5 →
IL4I1 L-amino-acid oxidase 0.982 landscape →
P70505 — 0.982 P70505 →
A6QQ07 — 0.982 A6QQ07 →
Q5R1W3 — 0.982 Q5R1W3 →
ERAP2 Endoplasmic reticulum aminopeptidase 2 0.981 landscape →
Q02401 — 0.981 Q02401 →
Q00495 — 0.981 Q00495 →
P35621 — 0.981 P35621 →